The Life Sciences Report: You manage two funds at BluMont—the BluMont Northern Rivers Innovation RSP Fund and the BluMont Innovation PE Strategy (BIPES) Fund I. Describe these funds and their differences from a very high-up perspective.
Hugh Cleland: Both funds focus on the tech and healthcare sectors and invest in publicly traded small- and micro-cap companies, with a few private investments sprinkled in. The Innovation PE Strategy Fund takes a private equity approach to investing, meaning it is a six-year fund with no redemptions. In the latter half of the fund’s life, we … [visit site to read more]
Similar posts:- Two Biotech Ideas You May Have Missed: William Gregozeski The Life Sciences Report: Bill, what industries do you follow?...
- Ross Silver on How to Find the Perfect Combo of Biotech Science and Market Savvy The Life Sciences Report: Your focus at Vista Partners is...
- Applying the Venture Capital Model to Public Companies: Hugh Cleland The Life Sciences Report: In your letter to investors dated...
